Active Pharmaceutical Ingredients (API) Market report focuses on the key player’s profiles in detail with granular analysis of the market share, production technology, market entry strategies, revenue forecasts and regional analysis of the market.
Active Pharmaceutical Ingredients Market outlook 2019 to 2023 is latest research on Active Pharmaceutical Ingredients global Market Research Report: Information by Manufacturing Process (Captive Manufacturing and Contract Manufacturing), Type of Synthesis (Synthetic and Biotech), by API Formulation (Generic API and Branded/Innovative API), Application (Cardiovascular Disease, Oncology, Neurological Disorders, Orthopedic Disorders, Respiratory, Gastrointestinal Disorders, Urology and others), Molecules (Large Molecule and Small Molecule) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) – outlook to 2023
Also Read : https://www.medgadget.com/2019/08/active-pharmaceutical-ingredients-api-market-global-size-largest-share-growth-competitor-landscape-regional-study-top-key-players-analysis-trends-and-industry-profits.html
Active Pharmaceutical Ingredients Market Report Analyzed By Top Key Players
Merck & Co. Inc., Boehringer Ingelheim GmbH, Novartis AG, Eli Lilly, Sanofi, Bayer AG, Pfizer Inc., F. Hoffmann-La Roche AG, Abbott Laboratories, GlaxoSmithKline Plc. (GSK), and Company and Teva Pharmaceutical Industries Ltd. are some of the prominent players in the global active pharmaceuticals market.
Active Pharmaceutical Ingredients Market Overview
Market Research Future (MRFR) sheds light on the growth of the active pharmaceutical ingredients (API) market, which is expected to achieve the valuation of USD 215.12 Bn by 2023. The report adds that the market is expected to surge at a CAGR of 4.93% during the forecast period (2015–2023).
Market Drivers and Key Restraints
The active pharmaceutical ingredients market gets a major boost from the growing prevalence of cardiovascular conditions, infectious diseases, and various other chronic disorders. Other than these, the rise in various genetic disorders has driven the use of biologicals and biosimilars, the world over. In many instances, biosimilars are the most preferred owing to them being low-cost. Biosimilars have the potential of creating a highly sustainable healthcare system which makes way for innovation, allowing more patients to receive the optimum care.
The growth of active pharmaceutical ingredients market is marked by the huge demand for drugs like analgesics, anti-infectives and diabetes, and pain management drugs. But with the rising trend of increasing research and development (R&D) activities, the demand is experiencing a shift towards the advancement of complex APIs that find use in novel formulations, thereby targeting niche therapeutic areas.
At present, a huge number of drugs are in the pipeline for the development of treatments for autoimmune disorders, metabolic diseases, and cancer. On account of the hike in the number of cancer cases, numerous manufacturers are now proceeding towards developing highly potent APIs as well as specialty APIs, in a bid to meet with the accelerated demand for such products. These factors are expected to have a remarkable effect on the market growth in the subsequent years.
The emergence of Highly Complex Active Pharmaceutical Ingredients
The latest generation of APIs being created is highly complex, which include high potency API, peptides, sterile API and oligonucleotides. This has led to more complicated R&D as well as certification processes.
Increasing Competition in the API Market
The rising number of small producers that have expertise in the manufacturing of niche APIs, has resulted in a highly stiff competition within the global market. Thus, the latest trend in the form of intensifying competitive nature of the market is projected to elevate the market position in the coming years.
The worldwide API market has been segmented on the basis of manufacturing process, type of synthesis, API formulation, application, molecule.
In terms of manufacturing, the market can be fragmented into captive manufacturing and contract manufacturing. Out of these, the contract manufacturing segment can expect a profitable run during the review period at the highest growth rate, backed by the increasing trend of outsourcing of API manufacturing by the pharmaceutical companies, which lets them focus more on core competencies.
Depending on the synthesis, the market is considered for synthetic and biotech, wherein the synthetic API market is set to be unbeatable with the maximum share of the global market. Meanwhile, the biotech segment has displayed a considerable growth pattern in recent years, which is expected to surge further at a relatively higher CAGR owing to the reduced side effects of biotech synthesis. Furthermore, the biotech segment is split into monoclonal antibodies, recombinant proteins, vaccines, and others. At present, the monoclonal antibodies segment holds the top position, whereas the recombinant proteins segment is slated to expand at the fastest rate during the appraisal period as recombinant proteins find an increasing number of applications within the pharmaceutical industry.
With respect to the API formulation, the market is categorized as generic API and innovative API. Growing patent expirations have been responsible for the leading position of the generic API segment, at a projected CAGR of 4.62% during the conjectured time frame.
The market, application-wise, can be broken down into cardiovascular disease, oncology, neurological disorders, orthopedic disorders, respiratory, gastrointestinal, urology, and others. Here, the oncology segment is the current holder of the biggest market share, since the occurrences of cancer has surged at a substantial pace around the world. The segment is deemed to rise at a growth rate of 5.48% in the coming years.
The API market, on the basis of molecule, caters to small molecule and large molecule. Although the report identified the small molecule segment as the largest market in 2017, the large molecule segment is reckoned to cross the former’s valuation at a higher CAGR in the near future. The main reasons being the increasing focus on research and development of advanced APIs, including biologics that strive to meet with the unmet needs of patients.
The key markets for active pharmaceutical ingredients include South America, Europe, Asia Pacific, North America, and the Middle East & Africa.
North America is spearheading the API market growth in the Americas, which in turn is leading the global market with the largest share. The crucial factors backing the said growth include the presence of a large number of prominent companies within the region. In addition, countries like the United States (U.S.) and Canada note high occurrences of chronic as well as neurological diseases, which is believed to be a prominent driver of the regional market growth.
Europe has bagged the second spot in the global API market, backed by the increasing number of initiatives within the region that support the development of generic drugs. Moreover, improving pricing, as well as reimbursement policies coupled with a huge number of manufacturing activities, is presenting multiple growth opportunities to the regional market.
As the active pharmaceutical ingredients market has reached the maturity phase in the developed countries around the globe, the market focus is shifting towards the Asia Pacific. This factor has substantiated the region as the fastest-growing market globally. The presence of a humungous patient population within countries like India and China paired with the rising incidences of chronic diseases in the region is poised to benefit the market in the subsequent years. On top of that, availability of cheap labor and need for low investments in infrastructure are encouraging several renowned pharmaceutical vendors to outsource manufacturing to Asia Pacific, opening the door for further market success.
OlonS.p.A., a global Active Pharmaceutical Ingredients (API) contract development and manufacturing organization (CDMO), has acquired a manufacturing facility in India. The facility’s primary product will be Rifampicin, which is used for treating a variety of bacterial infections, such as tuberculosis among others.